Medtech - An attractive market for private equity

Attractive business model coupled with market liquidity are driving up premiums however significant care should be taken on finding the right asset

Read more

Body countouring - The next botox?

Following Allergan's announcement on 13 February of its acquisition of bodycountouring specialist ZELTIQ for $2.7bn...

Read more

The future of UK pharmacies

UK pharmacy valuations have been on the rise driven by significantly more demand than supply for pharmacy acquisitions. The UK…

Read more


  • Moderna’s land grab December 8, 2018
    Moderna’s monster IPO gives the company a chance to validate the mRNA space across several treatment paradigms.
  • Path to opioid-free pain relief December 8, 2018
    Clarity on clinical outcomes could be the key to kick-starting development of non-opioid analgesics, an FDA panel meeting suggests.
  • Intermittent move beyond Blincyto December 8, 2018
    ASH data indicate the successor to Amgen’s BiTEs will be less about new targets and more about replacing a 28-day infusion with a less grueling regimen.
  • Novo gets serious about AI-guided drug design December 8, 2018
    Novo is integrating AI throughout its R&D org and creating semi-autonomous research units to drive its next wave of innovation.
  • ADCendo: entering tumors via MRC2 December 7, 2018
    ADCendo’s ADC against MRC2 could treat sarcoma and other cancers at lower doses and with less toxicity than competing ADCs.
  • Taking Tesaro December 7, 2018
    Despite fall in valuation, investors are positive on Tesaro’s portfolio strategy and deal value.
  • INKEF’s creative ambitions December 4, 2018
    Roel Bulthuis joins INKEF with plans to increase healthcare company creation in the Netherlands.
  • Cell therapy momentum at ASH December 1, 2018
    BioCentury’s analysis of clinical abstracts at ASH 2018 points to a surge in new CAR T strategies, while gene therapies lose momentum.
  • China’s germline growing pain December 1, 2018
    Chinese stakeholders want regulators to respond to the CRISPR baby uproar with more oversight of clinical trials, arguing it could boost the ecosystem.
  • Afyx: Mucosal drug delivery November 30, 2018
    Afyx is developing drug patches that could offer more controlled drug exposure than topical agents.